Académique Documents
Professionnel Documents
Culture Documents
5/27/13
virus could be accomplished, that might not cure the disease; the cellular transformation that occurred may no longer reversible. Some cases of chronic leukemia, notably CLL, are sufficiently innocuous that they are left without treatment for a time because the degree of imbalance in blood cell production is within tolerable limits; in most other cases, anticancer drugs are used in an effort to slow its progress. Some new techniques of treating leukemia have been developed, include destroying the cancerous bone marrow (thus eliminating the neoplastic cells) and transplanting healthy bone marrow (grown in the laboratory from donated marrow cells). Substantial success has been attained in treating acute childhood leukemia, especially ALL, which was, until recently, a major cause of childhood deaths (with peak incidence around 4 years of age). This positive outcome may be the result of two factors: in acute leukemia, the chemotherapeutic drugs have a much stronger effect on the highly active abnormal cells than on the normal cells; and in children the ability to recover normality is better than in older persons. Up to 90% of cases of childhood acute lymphocytic leukemia go into remission with treatment, with about 70% of treated cases gaining long-term survival (2). AML tends to strike in the age range of 15-39 years and has a moderately good response to treatment by bone marrow transplant, though long-term outcomes are not yet known. Cases of chronic leukemia are poorly managed by modern chemotherapy: the disabling effects of the therapy on the entire physiological function are often as strong as they are on the cancerous cells. Often, the individual must undergo multiple types of interventions, including blood transfusions, antibiotics, and other "supportive therapies." Progress towards a cure has been difficult. The age of diagnosis for chronic leukemia is typically between 40 and 60 years. Without treatment, chronic leukemia patients are expected to live for 2-6 years from onset of the disease; CML tends to progress more rapidly than CLL. However, about half of the patients with chronic leukemia die within two years of their diagnosis even with treatment. Slightly increased survival time after diagnosis in recent years may be the result of earlier detection more so than successful treatment. Busulfan (a.k.a. Myleran), a drug that has been frequently used for one type of chronic leukemia (granulocytic), commonly produces mean survival times of about 3-4 years. For leukemia in adults, it is reasonable to pursue Chinese medical therapies in an attempt to improve the outcomes.
www.itmonline.org/arts/leukemia.htm
2/13
5/27/13
Once the efforts of traditional Chinese doctors were turned to the problem of treating leukemia, it did not take long for certain antileukemic remedies to arise. According to Chang Zhinan of the Hematology Division of Capital Hospital in Beijing (3), leukemia (of modern diagnosis) has been subjected to various attempts at using Chinese materia medica items since about 1953. He reported that herbs have been applied for four purposes: reducing complications of leukemia, such as bleeding and infection; reducing adverse reactions to chemotherapy or increasing resistance of the body to adverse impact of leukemia; promoting the body's natural healing ability to reduce the impact and spread of the neoplastic process; and eradicating the leukemia cells. Today, there are basically three treatment methods: inhibit leukemia cells; promote the body function and protect it from leukemia and side effects of toxic treatments; and treat specific symptoms. These three will be analyzed below.
5/27/13
Western practitioners is all but precluded; in fact, concerns for heavy metal contamination of Chinese herbs, especially with arsenic and mercury (mainly from realgar and cinnabar, included in many formulas) are so great that it would probably cause significant legal problems if someone were to knowingly prescribe this as a medicinal agent. Other anticancer materials that the Chinese have used for leukemia include strychnos, camptotheca, cephalotaxus, celastrus, catharanthus, and toad secretion. These are all somewhat toxic and not used by Western practitioners. Cephalotaxus is related to the yew tree that yields the modern anticancer drug taxol; cephalotaxus has yielded the antileukemia drug harringtonine, which is extensively used in China, but not in the U.S. It is a treatment for acute monocytic leukemia (a type of AML). Camptotheca has been intensively studied in both the U.S. and China and yields the drug hydroxycamptothecin (used for acute myelocytic and lymphocytic leukemias), also not approved in the U.S. Strychnos, which contains strychnine, has anticancer properties but is not licensed for use here (it is an ingredient of the Chinese formula Ping Xiao Dan, used for many types of cancer). Celastrus contains dibromodulcitol, which is used to treat chronic granulocytic leukemia (same application as indigo). Catharanthus is the source of the standard chemotherapeutic agents vinblastine and leurocristine; these are used in treatment of ALL and AML. Toad secretion contains bufotoxin, which is highly irritating and not permitted for use in the U.S. (one case of bufotoxin fatal poisoning was recorded in the U.S. recently when an herbalist accidentally filled a prescription incorrectly and substituted this item, it was present at a dosage much higher than would normally be used). Toad secretion also contains bufotenine, a compound similar in structure to indirubin. A well-known, but somewhat toxic patent medicine, Liu Shen Wan, is sometimes recommended by Chinese doctors for leukemia: it includes toad secretion and realgar. A toad secretion prescription, originally applied topically for treatment of lip cancer, was later used to treat ALL, with some success. It also includes realgar, as well as other toxic materials, such as cinnabar and calomel (both contain mercury). These Chinese leukemia remedies have the same function as modern pharmacological interventions that we call chemotherapy. In fact, Chinese chemotherapy is sometimes simply derived from herbal active constituents, including harringtonine, indirubin, and hydroxycamptothecin. The purpose is to inhibit the abnormal bone marrow cells, so as to permit the growth and function of the normal cells. In China, there are more of these drugs available than in the U.S. as the result of fewer restrictions on drug licensing.
Anti-CML Pill
The discovery that indigo was clinically effective for leukemia was made in the early 1960's, when researchers at the Institute of Hematology, Chinese Academy of Sciences (Beijing) noted that an herbal formula prescribed by Chinese doctors appeared to be producing good results in many patients. The formula, Danggui Luhui Wan, included indigo as an ingredient and had prominent action in cases of chronic myelocytic leukemia (CML). The formula also contains tang-kuei, gentiana, coptis, phellodendron, scute, rhubarb, aloe, saussurea, and musk, and was traditionally used for reducing fever, purging intense heat, and removing toxin. A modified version of the traditional formula, which includes both indigo and realgar, was developed at this Institute, and reported to be even more effective than the original: it was called the anti-CML pill. It contains indigo, realgar, ranunculus, sophora, scute, phellodendron, tang-kuei, terminalia, leech, and eupolyphaga. The basis for adding realgar to the indigo was that potassium arsenite, a related compound, had previously been used for treating CML by Western-style practitioners (in the 1940s), but had been abandoned due to toxicity problems. The lower toxicity of realgar may be due solely to differences in rates of absorption from the
www.itmonline.org/arts/leukemia.htm 4/13
5/27/13
intestinal tract. Realgar was substituted for potassium arsenite and reported effective in 1960 by a hospital in Shanghai. It was found in one small study in 1970 that complete remission could be attained in some leukemia patients by administering 9-18 grams of realgar per day (by decocting it, where only a fraction is solubilized; usual dosages of orally ingested powder are less than 2 grams per day). The adverse effects were less than those of potassium arsenite. Another toxic arsenic compound formula, made with arsenic oxide, was reported by a group in Harbin to be reasonably effective for acute myelocytic leukemia. According to the author of Anticancer Medicinal Plants , realgar is also single remedy for chronic granulocytic leukemia, taken at a dose of 0.3-0.9 grams each time, one or two times daily. Indigo had been tested as a single herb remedy for CML in the 1970s. A dose of 6-12 grams per day was reported to achieve complete or partial remission. The remission rate increased when realgar was added as 11% of the formula (for example: 1 gram realgar mixed with 8 grams indigo). Recent treatments in China continued to rely on the crude material for some time, even though indirubin is available. As an example, Qinghuang Powder, prescribed at the Xiyuan Hospital for treating chronic granulocytic leukemia, is made of a 9:1 ratio of indigo and realgar, given in capsule form, with a daily dosage of 6-14 grams, divided into three doses; a maintenance dosage, after improvement is attained, is 3-6 grams per day. The anti-CML pill is reported, by the group that worked with it, to be more effective than indigo-realgar treatment alone. The reason for this is not yet established. Other ingredients in the pill include sophora root (which contains the anticancer ingredient matrine) and tang-kuei, which may serve in a protective role. Arsenic levels of patients taking this pill were monitored by urine analysis. Chronic arsenic intoxication produces changes in the skin, with pruritis, skin pigmentation, and keratodermia, and it may cause mild peripheral neuritis. If such occurred, arsenic was cleared from the system using sodium dimercaptopropan sulfonate or sodium dimercaptosuccinate. By simply stopping the use of the anti-CML pill, urinary excretion of arsenic would reduce over a period of 1-6 months. The researchers working with the anti-CML pill felt that the problem of arsenic toxicity was manageable. In the U.S., the only one of the specific anti-leukemic substances that can be reasonably prescribed is indigo (qingdai). When Chinese immigrant doctors have prescribed encapsulated indigo to their patients it is usually administered at doses far lower than the 6-12 grams reported above (typical amounts are 1-3 grams).
5/27/13
months. The same results were reported in another comparative trial with busulfan alone versus alternating treatment with busulfan and an herbal pill, similar to the anti-CML pill, called Manli Wan (composed of ranunculus, sophora, scute, phellodendron, tang-kuei, terminalia, indigo, eupolyphaga, and leech). These alternating strategies are deemed interesting to Western-trained Chinese doctors because the busulfan is so toxic. In a long-term study of indirubin treatment for CML, it was reported that "maintenance therapy [with indirubin] was necessary for CML patients after achieving complete remission and there was no obvious side effects over long-term administration of the drug. Unfortunately, indirubin could not suspend or postpone development of blastic crisis (7)." Median survival time in this study of 57 cases of CML treated with the simple protocol of indirubin administration was 31.5 months. Put simply, remission of leukemia is usually a temporary condition. Improvement in the quality of life of patients is also a major factor, despite any changes in blood picture or duration of life. The proponents of Chinese medicine suggest that rates of complete and partial remission and quality of life are improved by using Chinese medicine, but the duration of survival may increase only slightly (by a few months), if at all. About 20% of chronic leukemia patients can attain survival times of 10 years or more.
5/27/13
ingredients can be understood in terms of presenting symptoms: lithospermum, raw, rehmannia, and rhino horn, for example, are used for high fever and spontaneous bleeding; turtle shell and tortoise shell not only nourish the blood and yin, but also prevent hemorrhage. The anti-leukemic substance, indigo, is provided in the highest quantity usually recommended. The difficulty with this approach is that the very high dosage decoction (over 200 grams per day) would have an extremely bitter taste and would likely have an irritating and even an inhibiting effect on the digestive system (which is probably already weakened by the disease and prior treatments). Therefore, one would hope to use a different prescription, such as the others offered in that book and described below. A common complaint of leukemia patients is chronic low grade fever and fatigue. This is the combined result of deficient blood status, side effects of cancer therapies, and secondary effects of continuing leukemia (especially the high metabolic status of the white blood cells). A recommended treatment is to use 24 grams of salvia, 20 grams millettia, 20 grams agrimony and 6-15 grams each of the following: ginseng, red peony, tangkuei, cnidium, persica, astragalus, hoelen, atractylodes, licorice, and pseudostellaria. This formula nourishes qi and blood and vitalizes blood circulation. It is to be used in conjunction with chemotherapy to enhance its effects and alleviate the characteristic symptoms the patient faces. This formulation, although high in dosage, has a tolerable taste and is unlikely to cause gastro-intestinal irritation; to the contrary, it has herbs that may improve the condition of the gastro-intestinal system. Other complementary formulas for leukemia recommended in this book focus more on tonic actions, by combining yin tonics (for those showing more evident signs of yin deficiency) or tonics for the qi and essence (for those showing overall deficiency syndrome). The formulas for leukemia patients do not differ significantly from those that might be used in various types of cancers in which the patient is receiving chemotherapy. That is, the fact that leukemia is being treated does not strongly influence the selection of herbs or formulations. The patient ought to be evaluated for evidence of the common problems of blood stasis, yin deficiency, qi deficiency, essence deficiency, organ swelling, etc., and treated accordingly. In each case, a total daily dosage of about 200 grams is recommended in this book. These dosages are impractical for American patients, who are not used to taking such decoctions. Even when using dried decoctions, a total daily dosage of 30 grams of the powders (corresponding to about 150 grams of crude herbs in decoction) is usually deemed too much. However, a lower total dosage might be successfully used if a smaller number of herbs are selected and if they closely match the Oriental diagnosis of patient requirements. In some of the Chinese reports on treating leukemia patients, general anticancer herbs that are non-toxic or of low toxicity, such as scutellaria, oldenlandia, solanum (lyratum or nigrum), and paris, are included in the formulas. It is not known at this time whether these have a specific antileukemic effect.
5/27/13
4. Swelling of the liver, spleen, lymph nodes, etc.: treated with herbs that resolve masses. Examples are laminaria, sargassum, oyster shell, curcuma, chih-ko (or other citrus materials), pangolin scales. 5. Ulceration and swelling of the gums, tongue, and oral cavity: treated with herbs that alleviate aphthae, such as fire-purging agents. Examples are coptis, gardenia, raw licorice, borneol. 6. Skin eruptions and purple maculae: treated with herbs that promote blood circulation and clean toxins. Examples are red peony, dandelion, carthamus, salvia, lonicera. 7. Aching: treated by herbs that regulate qi and blood and analgesic herbs. Examples are corydalis, pteropus, typha, cyperus, lindera, sandalwood. In each of the cases, these agents are selected according to standard principles of Oriental diagnostics and prescribing, with no special reference to the source of the symptoms as being leukemia. One can see from untreated cases that this disease would be diagnosed as a syndrome involving pathogenic heat in the blood. Such a condition would help to explain several symptoms, such as fevers, bleeding (and appearance of purple maculae), skin eruptions, and ulceration and swelling in the oral cavity. Not surprisingly, the traditional remedies are often based on formulas for such symptoms that might arise as well from other causes. The Rhino and Rehmannia Combination is one such formula. The traditional formulas can be modified by adding one or more blood tonics to address the anemia, and one or more herbs for dispersing accumulations to treat the organ swelling and accompanying aching. The Danggui Luhui Wan formula, that includes indigo and was at the basis of the anti-CML pill, is an example; it contains saussurea, rhubarb, aloe, and musk to help get rid of accumulations.
5/27/13
In another trial of indirubin plus herbs for chronic granulocytic leukemia (14), patients were treated by indirubin, 50 mg each time, 3 times daily. Herbs given according to syndrome differentiation: 1. Qi Stagnation with Liver/Spleen Enlargement: ching-hao, lycium bark, red peony, moutan, sparganium, zedoaria, salvia, solanum lyratum, oldenlandia, cremastra, turtle shell, tortoise shell, gardenia, chih-ko, rhubarb, licorice (each item, 9-15 grams, except 30 grams oldenlandia). Note that solanum, oldenlandia, and cremastra are general anti-cancer herbs. 2. Qi and Yin Deficiency: pseudostellaria, asparagus, rehmannia, ching-hao, lycium bark, oldenlandia, solanum nigrum, scutellaria, eclipta, lycium fruit, turtle shell, sophora subprostrata, forsythia, lonicera stem, gallus, baked licorice (each item, 9-15 grams, except 30 grams oldenlandia). In this formula, oldenlandia, solanum, scutellaria, and sophora subprostrata are general anti-cancer herbs. Complete remission was attained in 40% of the patients, partial remission in 50%, no benefit in 10%. About 15 days of treatment were required to reduce spleen enlargement, with normalization after about 40 days. Leukocyte levels began to show decline after about 10 days, with 60 days treatment required to get to the normal range in responsive patients. Long-term results were not reported. This study reveals that one can monitor the effectiveness of the treatment by checking leukocyte levels over a two month period.
5/27/13
to the anti-CML pill may be of value for myologenous leukemias. This approach usually relies on the use of indigo as the primary therapy, with various supporting herbs to be included in the treatment, probably in the form of dried decoctions (formula designed by the practitioner), or, if the patient is unwilling to use that method, tableted formulas (in large quantities). A monthly blood draw can be used to monitor the progress of the treatment, along with the standard examination of symptom changes. Indigo can be provided in capsules, starting at a dose of about 1 gram per day and working up to 6 grams per day, or up to tolerance levels. Once the maximum level has been determined, herbal combinations should likewise be administered starting at a modest dosage and working up to a maximum possible dosage. For example: using decoctions, begin at 30 grams per day; using dried decoctions, start at 6 grams per day, using tableted formulas, start at 9 tablets per day. Let the patient know about the high dosage form of natural materials. The ability to ingest and tolerate large amounts of herbs (and, possibly, nutritional supplements) may be a key to success with this natural approach. It has been reported that indirubin used for an extended period of time may cause pulmonary hypertension and cardiac insufficiency in some patients (10). This effect, which occurred in persons treated for 9 months to 3 years, was slowly reversed when the indirubin was removed. Presumably, this adverse reaction could occur with administration of the higher doses of natural indigo, as it contains indirubin. Therefore, any patients who are to be treated for 9 months or longer should have their cardiac function monitored. While specific nutritional approaches have not been developed for leukemia, certain general methods can be applied: 1. Make sure the individual is receiving adequate basic dietary nutrients, such as proteins, fats (preferably unsaturated), and carbohydrates. Monitor body weight and muscle strength, and take further action if there is not improvement, including recommending easy-to-use concentrated nutrition sources. 2. Provide additional nutrients and a high level of antioxidants using supplements (11). General anticancer substances may be tried, including flavonoids (quercetin, genestein, tea polyphenols), minerals (selenium), and vitamins (high dose vitamins A, C, and E). Even if these fail to produce a cancer-inhibiting action, they may provide other benefits for persons in the age group that suffers from chronic leukemia. 3. When possible, use Oriental dietary techniques to match the dietary components to the symptom/sign pattern (12). For example, use cooling foods for fevers, astringent foods for sweating, yin-nourishing foods for yin deficiency patterns, etc. Make sure the suggestions include using foods that can reasonably be obtained and prepared. The relative deficiency of reports in the Chinese literature regarding treatment of chronic lymphocytic leukemia (CLL) with herbs is mainly due to the fact that CLL is very rare in the Orient, due to genetic factors. Although a few recipes for treatment (based on traditional principles for treating the symptom presentation) have been published, evidence for their effectiveness is lacking because of insufficient case studies. The approach to be taken would be to treat according to the traditional syndrome differentiation, in combination with standard chemotherapy when possible. Chronic granulocytic leukemia appears to be the type of leukemia most intensively investigated, no doubt as a response to early findings of benefit from using traditional Chinese herbal materials coupled with a relatively high frequency of incidence in China. Acute leukemia is always treated with a chemotherapy, with reported improvements attained by adding Chinese herbal therapies.
www.itmonline.org/arts/leukemia.htm 10/13
5/27/13
5/27/13
3. Qi and blood deficiency type: astragalus, codonopsis, atractylodes, hoelen, tang-kuei, gelatin, lycium fruit, psoralea, ho-shou-wu, oldenlandia, cirsium, salvia, and millettia, all in heavy dosage of 15-30 grams. The Western medical treatments were also differentiated according to whether the disease was the acute lymphocytic type, acute non-lymphocytic type, or acute granulocytic type. Of 35 patients in the integrated therapy group, 69% had complete remission and 20% had partial remission, with 11% not improved; of 35 patients in the Western medicine group 43% had complete remission, and 20% had partial remission, with 37% not improved. Survival time was reported to be longer in the integrated group than the partial remission group, but the details in the report were unclear. An article (17) describing treatment of a small number of patients with refractory recurrent acute leukemia, indicated that those who failed to attain remission by chemotherapy alone could sometimes gain benefit from combined therapy with Chinese herbs. Sixteen patients were treated according to syndrome differentiation, all having internal pathogenic heat, with four subtypes: qi and yin deficiency; damp-heat plus blood stasis; phlegm nodules; blood stasis with movable mass. In each case, a decoction was given to address the syndrome. It was reported that 10 of the patients had complete remission, and 2 patients had partial remission as a result of using 1-4 months of therapy, an average of 3 months.
References
1. Robbins SL, Cotran RS, and Kumar V, Pathologic Basis of Disease (3rd Ed.), 1984 W.B. Saunders Company, Philadelphia, PA. 2. Boik J, Cancer and Natural Medicine , 1995 Oregon Medical Press, Princeton, MN. 3. Hson-Mou Chang, et al., Advances in Chinese Medicinal Materials Research, 1985 World Scientific, Singapore. 4. Hson-Mou Chang and Paul Pui-Hay But (eds.), Pharmacology and Applications of Chinese Materia Medica, (2 vols.), 1986 World Scientific, Singapore. 5. Chang Minyi, Anticancer Medicinal Herbs , 1992 Hunan Science and Technology Publishing House, Changsha. 6. Leake CD, Historical Account of Pharmacology to the Twentieth Century, 1975 Charles C Thomas, Springfield, IL. 7. Qian Linsheng, et al., "Observation on the long period effect of indirubin in the treatment of 57 cases of chronic myelogenous leukemia," Chinese Journal of Hematology 1991; 12(3): 125-127. 8. Pan Mingji, Cancer Treatment with Fu Zheng Pei Ben Principle , 1992 Fujian Science and Technology Publishing House, Fujian. 9. Sun Chiyuan, A Probing into the Treatment of Leukemia with Traditional Chinese Medicine , 1990 Hai Feng Publishing Company, Hong Kong. 10. Jiang Shuzhen, Yu Gong, and Cao Jinni, "Adverse effect of indirubin on the cardiovascular system, a report of 3 cases," Chinese Journal of Hematology 1986; 7(1): 30. 11. Werbach M, Nutritional Influences on Illness , 1993 Third Line Press, Tarzana, CA. 12. Lu HC, Chinese System of Food Cures , 1986 Sterling Publishing Co. Inc., New York, NY.
www.itmonline.org/arts/leukemia.htm 12/13
5/27/13
13. Tao Shuchun, "Observation on clinical effect of 80 cases of chronic granulocytic leukemia treated with Chinese medicine mainly," Journal of Traditional Chinese Medicine, 1997 38(6): 349-350. 14. Yin Pingping, "Observation on clinical effect of 20 cases of chronic granulocytic leukemia," Shanghai Journal of Traditional Chinese Medicine 1997; (6): 31. 15. Deng Youan, et al., "Additional use of blood-activating Chinese herbs in chemotherapy of acute leukemia," Sanxi Medical Journal 1988; 17(2): 79-81. 16. Yan Yi, "Analysis of therapeutic effectiveness in 35 cases of acute leukemia with therapy by Chinese integrated medicine," Chinese Journal of Integrated Traditional Chinese and Western Medicine 1995; 15 (1): 643-645. 17. Wang Jiliang, "Clinical research on treatment of 16 patients with refractory recurrent acute leukemia," Practical Journal Integrating Chinese and Modern Medicine 1996; 9(3): 138. 18. Ou Ming, et al., An Illustrated Guide to Antineoplastic Chinese Herbal Medicine , 1990 Commercial Press, Hong Kong.
December 1997
www.itmonline.org/arts/leukemia.htm
13/13